COMMUNIQUÉ DE PRESSE publié le 30/09/2024 à 13:00, il y a 1 année 11 mois Moderna Announces First Participant Dosed in Pivotal Phase 3 Trial of Investigational mRNA Norovirus Vaccine, mRNA-1403 Moderna initiates Phase 3 trial for mRNA-1403, an investigational norovirus vaccine, aiming to prevent infection from norovirus. Global recruitment has started Moderna Phase 3 Trial MRNA-1403 Norovirus Vaccine Global Recruitment
COMMUNIQUÉ DE PRESSE publié le 30/09/2024 à 13:00, il y a 1 année 11 mois Significant Metallurgical Advancement: Moving Toward a New Industry Standard for LiFePO4 Battery Feedstock St-Georges Metallurgy Corp., a leader in mineral processing technologies, advances lithium processing with a novel one-step LiFePO4 production process. Collaboration with partners aims for cost-effective battery feedstock production and environmental sustainability Environmental Sustainability Lithium Processing St-Georges Metallurgy Corp. LiFePO4 Production Battery Feedstock
COMMUNIQUÉ DE PRESSE publié le 30/09/2024 à 12:48, il y a 1 année 11 mois EQS-Adhoc: Blue Cap AG sells subsidiary nokra to Vishal Precision Group Blue Cap AG sells nokra to Vishal Precision Group, generating single-digit million proceeds. Agreement includes 90% stake sale and 6x capital employed multiple Blue Cap AG Sale Proceeds Nokra Vishal Precision Group
COMMUNIQUÉ DE PRESSE publié le 30/09/2024 à 12:40, il y a 1 année 11 mois Photon Energy to Run FORVIA’s First On-Site PPA Solar Power Plant in Hungary Photon Energy completes construction of 658 kWp solar power plant in Hungary under PPA with FORVIA's Clarion Hungary, contributing to reduced CO2 emissions and long-term energy cost savings Photon Energy PPA Solar Power Plant Hungary Forvia
COMMUNIQUÉ DE PRESSE publié le 30/09/2024 à 12:30, il y a 1 année 11 mois NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 Progressing to Phase II Clinical Trial - Multiple Indications of NV-387 Include RSV, Influenza, MPOX/Smallpox, COVID NanoViricides, Inc. reports filing of Annual Report on Form 10-K for fiscal year 2024, financial updates, and plans for Phase II clinical trials of antiviral drug NV-387 NanoViricides NV-387 Financial Updates Form 10-K Phase II Clinical Trials
COMMUNIQUÉ RÉGLEMENTÉ publié le 30/09/2024 à 12:05, il y a 1 année 11 mois Statement of transactions in own shares from September 23, 2024 to September 27, 2024
COMMUNIQUÉ RÉGLEMENTÉ publié le 30/09/2024 à 12:04, il y a 1 année 11 mois Déclaration des transactions sur actions propres réalisées du 23/09/2024 au 27/09/2024
COMMUNIQUÉ DE PRESSE publié le 30/09/2024 à 12:00, il y a 1 année 11 mois Medacta Hosts Inaugural Capital Markets Day, Showcasing Responsible Innovation and Effective Growth Strategy Medacta Group SA hosts its first Capital Markets Day, presenting responsible innovation and effective growth strategy to investors. Key areas include patient-focused commitment, product development, and global market expansion Growth Strategy Capital Markets Day Medacta Group SA Responsible Innovation Patient-focused Commitment
COMMUNIQUÉ DE PRESSE publié le 30/09/2024 à 12:00, il y a 1 année 11 mois DEMIRE achieves 2023 guidance for rental income and FFO, successful bond refinancing to be implemented in the coming weeks DEMIRE achieves 2023 guidance for rental income and FFO. Successful bond refinancing in progress. Market devaluations and portfolio adjustments highlighted Rental Income FFO Bond Refinancing DEMIRE Portfolio Adjustments
COMMUNIQUÉ DE PRESSE publié le 30/09/2024 à 12:00, il y a 1 année 11 mois beaconsmind Group announces 1H2024 with strong profitable growth reaffirming previously provided guidance for full year 2024 beaconsmind Group reports strong profitable growth in 1H2024 with revenue up by 122% and EBITDA up by 740% compared to previous periods. Cash breakeven achieved and positive free cash flow expected. Major client wins and expansion plans highlighted Profitable Growth Beaconsmind Group 1H2024 Results Cash Breakeven Client Wins
Publié le 11/09/2026 à 07:00, il y a 1 jour 6 heures BIOPHYTIS ANNOUNCES COMPLETION OF €5.3 MILLION CAPITAL INCREASE TO FUND ITS PHASE 2 TRIAL IN OBESITY
Publié le 11/09/2026 à 07:00, il y a 1 jour 6 heures BIOPHYTIS ANNONCE LA RÉALISATION D’UNE AUGMENTATION DE CAPITAL DE 5,3 MILLIONS D’EUROS DESTINÉE À FINANCER SON ESSAI DE PHASE 2 DANS L’OBÉSITÉ
Publié le 10/09/2026 à 19:30, il y a 1 jour 17 heures Availability of the 2026 Interim Financial Report
Publié le 12/09/2026 à 02:35, il y a 10 heures 53 minutes Gamma Resources Announces Extension of Private Placement Closing Date
Publié le 11/09/2026 à 23:00, il y a 14 heures 28 minutes Rio Grande Resources Engages Machai Capital for Investor Outreach
Publié le 11/09/2026 à 22:05, il y a 15 heures 23 minutes Usha Resources Announces Leadership Transition
Publié le 11/09/2026 à 21:25, il y a 16 heures 3 minutes Algo Grande Copper Intersects 30.23 Metres Grading 1.5% CuEq, including 3.55 Metres at 9.4% CuEq and 1.2-Metre Interval at 15.8% CuEq, 100 Metres Vertical Step-Out from Historical Intersects
Publié le 11/09/2026 à 17:00, il y a 20 heures 28 minutes Critical Elements Selected for Canada Investment Summit Prospectus, Showcasing Project to Leading Global Investors
Publié le 12/09/2026 à 07:30, il y a 5 heures 57 minutes NAGRAVISION Secures Formula 1 Content for RTL Croatia and PRO PLUS Slovenia
Publié le 11/09/2026 à 22:15, il y a 15 heures 13 minutes Amrize Appoints Mario Gross as President of Building Envelope
Publié le 11/09/2026 à 22:10, il y a 15 heures 17 minutes Quantinuum to Participate in the Piper Sandler 5th Annual Growth Frontiers Conference
Publié le 11/09/2026 à 19:44, il y a 17 heures 43 minutes DocMorris announces final conversion price and issue size of its New Convertible Bonds due 2031
Publié le 11/09/2026 à 18:15, il y a 19 heures 12 minutes CGTN: How BRICS creates new opportunities for Global South development